European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA (2011) AIDS 25: 37-47 Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV, AIDS Clinical Trials Group (ACTG) A5142 Study Team (2009) AIDS 23: 1109-18 Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Motsinger AA, Kallianpur AR, AIDS Clinical Trials Group 384 and A5005s Study Teams (2008) J Infect Dis 197: 858-66 Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Martin AM, Nolan D, Gaudieri S, Phillips E, Mallal S (2004) Pharmacogenomics 5: 643-55 Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected Black South Africans: a pilot study. Sinxadi PZ, Dave JA, Samuels DC, Heckmann JM, Maartens G, Levitt NS, Wester CW, Haas DW, Hulgan T (2013) AIDS Res Hum Retroviruses 29: 1031-9
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.